Clinical Trial Update: BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for BIO 300 oral suspension in previously hospitalized Long COVID patients; current status and results are not provided in the available sn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection
• Pulmonary Fibrosis

Drugs mentioned

• BIO 300

Snippet

Sponsor: Humanetics Corporation | Conditions: COVID-19, Long COVID | Phase 2 | Status: UNKNOWN